Head to Head Survey: Axsome Therapeutics (AXSM) versus GW Pharmaceuticals PLC- (GWPH)

Axsome Therapeutics (NASDAQ: AXSM) and GW Pharmaceuticals PLC- (NASDAQ:GWPH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Axsome Therapeutics and GW Pharmaceuticals PLC-, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics 0 0 4 0 3.00
GW Pharmaceuticals PLC- 0 1 6 0 2.86

Axsome Therapeutics presently has a consensus price target of $19.50, indicating a potential upside of 584.21%. GW Pharmaceuticals PLC- has a consensus price target of $150.29, indicating a potential upside of 25.34%. Given Axsome Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than GW Pharmaceuticals PLC-.


This table compares Axsome Therapeutics and GW Pharmaceuticals PLC-‘s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Axsome Therapeutics N/A -132.28% -73.69%
GW Pharmaceuticals PLC- -1,357.98% -46.94% -41.00%

Institutional and Insider Ownership

22.9% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 82.7% of GW Pharmaceuticals PLC- shares are owned by institutional investors. 35.2% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Axsome Therapeutics and GW Pharmaceuticals PLC-‘s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Axsome Therapeutics N/A N/A -$28.94 million ($1.29) -2.21
GW Pharmaceuticals PLC- $11.00 million 302.69 -$166.90 million ($8.85) -13.55

Axsome Therapeutics has higher earnings, but lower revenue than GW Pharmaceuticals PLC-. GW Pharmaceuticals PLC- is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.


Axsome Therapeutics beats GW Pharmaceuticals PLC- on 7 of the 12 factors compared between the two stocks.

About Axsome Therapeutics

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company’s commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply